Pre-Exposure Prophylaxis study (treated before exposed to the virus)
et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217690 (Letter)
Baseline use of hydroxych loroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19
Analysis of 80 SLE patients diagnosed with COVID-19, showing the frequency of hospitalisation did not differ between individuals using an antimalarial versus non-users (55% (16/29) vs 57% (29/51), p
=ns. Authors suggest that the dosage used may be too low to reach therapeutic levels.
hospitalization, ↓3.0%, p=0.88
Please send us corrections, updates, or comments.